Lögdberg L, Kaplan E, Drelich M, Harfeldt E, Gunn H, Ehrlich P, Dottavio D, Lake P, Ostberg L
Monoclonal Antibody Research, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
J Med Primatol. 1994 Jul;23(5):285-97. doi: 10.1111/j.1600-0684.1994.tb00286.x.
The feasibility to raise nonhuman primate antibodies against selected components of the human immune system was tested. The immunogens were whole cells (human T lymphocytes) or purified, recombinant human proteins (cytokines: TNF alpha or GM-CSF; soluble forms of cell surface antigens: sCD4 or sCD25). Significant immunizations, yielding functionally relevant antibodies, were readily achieved in rhesus monkeys, but, not surprisingly, may be less frequent in chimpanzees. The results suggest a general strategy for production of therapeutically useful MAB.
测试了产生针对人类免疫系统选定成分的非人灵长类动物抗体的可行性。免疫原是全细胞(人类T淋巴细胞)或纯化的重组人类蛋白质(细胞因子:肿瘤坏死因子α或粒细胞巨噬细胞集落刺激因子;细胞表面抗原的可溶性形式:可溶性CD4或可溶性CD25)。在恒河猴中很容易实现显著的免疫反应,产生功能相关的抗体,但不出所料,在黑猩猩中可能不太常见。结果提示了一种生产治疗用单克隆抗体的通用策略。